【藥品庫存】 本藥品為臨時採購藥品，經院長核可後，限定特定科別、病人使用。 【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人(除非用於癲癇、調節情緒)。

治療癲癇 Lennox-Gastaut syndrome
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in adults and children 1 year and older

Anticonvulsant, Triazole Derivative
A triazole-derivative antiepileptic whose exact mechanism is unknown. In vitro, it prolongs the inactive state of the sodium channels, thereby limiting repetitive firing of sodium-dependent action potentials mediating anticonvulsant effects.

Absorption:
1. Slow; increased with food
2. Bioavailability: Extent decreased with increased dose
Distribution:
1. Vd: ~50 L
2. Protein binding: 34%, primarily to albumin (27%)
Metabolism:
Extensively via carboxylesterase-mediated hydrolysis of the carboxylamide group to CGP 47292 (inactive metabolite); weak inhibitor of CYP2E1 and weak inducer of CYP3A4
Excretion:
Urine (85%, ~66% as CGP 47292, 2% as unchanged drug)
Pharmacodynamics:
1. Half-life elimination: ~6 to 10 hours
2. Time to peak, plasma: 4 to 6 hours

Patients with familial short QT syndrome

Adverse effects were seen in animal reproduction studies.

It is not known if rufinamide is present in breast milk.

Cardiovascular: Shortened QT interval (46% to 65%; dose related)
Central nervous system: Headache (adults 27%, children 16%), drowsiness (11% to 24%), dizziness (3% to 19%), fatigue (9% to 16%)
Gastrointestinal: Vomiting (children 17%, adults 5%), nausea (7% to 12%)

400 to 800 mg daily in 2 equally divided doses; increase dose by 400 to 800 mg daily every other day to a maximum dose of 3,200 mg daily in 2 equally divided doses

Children and Adolescents <17 years:
1. Initial: 10 mg/kg/day in 2 equally divided doses; increase dose by ~10 mg/kg increments every other day to a target daily dose of 45 mg/kg/day in 2 equally divided doses
2. Maximum daily dose: 3,200 mg/day; effectiveness of doses lower than the target dose is unknown
Adolescents ≤17 years:
1. Initial: 400 to 800 mg/day in 2 equally divided doses; increase dose by 400 to 800 mg daily every other day to a maximum daily dose of 3,200 mg/day in 2 equally divided doses
2. Effectiveness of doses lower than 3,200 mg/day is unknown

1. CrCl <30 mL/minute: No dosage adjustment necessary.
2. Hemodialysis: Noo dosage adjustments provided in the manufacturer's labeling. However, consider dosage adjustment for loss of drug.

1. Mild to moderate impairment (Child-Pugh score 5 to 9): Use with caution.
2. Severe impairment (Child-Pugh score 10 to 15): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use is not recommended.